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Abstract 
This article outlines current guidelines for the pharmacological treatment of depression. For acute 
treatment of moderate to severe depression in the absence of specific factors, the recommendation 
is treatment with a selective serotonin reuptake inhibitor or mirtazapine. Other options for acute 
antidepressant treatment are discussed, and advantages and disadvantages of specific drugs are 
outlined. Recommendations for next-step treatment for patients with an inadequate response 
include increasing the dose, switching to another antidepressant, augmentation with another agent 
or using a combination of antidepressants. Again, recommendations for specific drugs are outlined, 
and the common advantages and disadvantages of specific drugs are listed in a table format. The 
options for non-pharmacological treatments are briefly explored in regards to symptom severity and 
other clinical features, and a list of non-pharmacological treatment options is provided. 
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Key Points 
 Correct diagnosis is crucial for the successful management of depression 
 Antidepressant medication is recommended as a first-line treatment for moderate to severe 
or for chronic depression 
 In the absence of specific factors, selective serotonin reuptake inhibitors or mirtazapine are 
recommended for the acute treatment of depression 
 Increasing the dose, switching to another antidepressant, augmentation with another agent 
and a combination of antidepressants are recommended as ‘next-step’ treatments 
 
 
  
Diagnosis 
A correct diagnosis of a specific depressive disorder and  its severity, chronicity and risk factors is 
crucial for successful management. Clinicians should have a good working knowledge of diagnostic 
criteria and be watchful for depressive symptoms in vulnerable groups, but there is no evidence of 
direct benefit from non-targeted screening.1  
Most cases can be managed in primary care.  Management should include scheduled follow-
up with monitoring of symptoms (ideally using standardized outcome measures) and functional 
recovery, but also focus on adherence to medications. Active case management interventions can be 
beneficial but are not in widespread use.  
Patients should be referred to a psychiatric service if there is a high suicide risk, occurrence of 
psychotic symptoms or suspicion of bipolar disorder, if there has been insufficient response to 
treatment and/or if the primary care professional feels insufficiently experienced to manage the 
case.2 In addition, all cases involving a child or adolescent presenting with depressive disorder 
should be referred to the relevant psychiatric services.3  
 
Acute treatment and management 
Antidepressant medication is a first-line treatment for moderate and severe depression and for any 
depression continuing for ≥2 years. Antidepressants should also be considered in patients with 
currently mild depression who have a past history of moderate or severe depression, or where 
symptoms have persisted for >2–3 months. Antidepressants are not recommended as first-line 
treatment for mild depressive symptoms of shorter duration unless there is a previous history of 
recurrent moderate to severe depression.2 Similarly, pharmacological management is not 
recommended for children or adolescents with depression unless they suffer from severe symptoms, 
there has been an insufficient response to alternative treatment and/or there is a past history of 
recurrent moderate to severe depression.3  
Psychological therapies are an alternative first-line treatment for mild to moderate 
depression, and the combination of medication and psychological therapy is recommended in more 
complicated cases such as chronic, severe, highly recurrent or treatment-resistant depression.1  
Most antidepressant drugs have broadly similar efficacy, and the choice of specific drug 
should be based on several factors including the efficacy of drugs on specific symptoms, interaction 
with other drugs and safety in overdose.1 In the absence of specific factors, the Maudsley Prescribing 
Guidelines in Psychiatry4 recommend a selective serotonin reuptake inhibitor (SSRI) or mirtazapine 
as first-line treatment because of better tolerability and safety; however, other drugs can be 
selected based on history of previous responses or specific effects on symptoms (see Table 1 for 
details on the benefits and disadvantages of specific drugs).  
There are few sufficiently powered head-to-head studies directly comparing different 
antidepressants, but there may be small benefits for escitalopram, sertraline, venlafaxine, 
mirtazapine, clomipramine and amitriptyline; in more severely ill patients, and in other situations 
where maximizing efficacy is of overriding importance, these are recommended in preference.1 
Combination treatment with antidepressant and antipsychotic medication (e.g. venlafaxine with 
quetiapine) is more effective than monotherapy for the treatment of depression with psychotic 
symptoms. Other factors affecting the choice of antidepressant include:  
 patient preference (particularly for medication versus psychological therapy) 
 psychiatric and medical co-morbidity, for example using serotonergic antidepressants for co-
morbid obsessive-compulsive disorder  or generalized anxiety disorder, and  tricyclic 
antidepressants (TCAs) for chronic pain 
  interactions with other medications  
 previous response to a particular medication 
 effects on specific depressive symptoms, such as appetite or sleep 
 adverse effects.  
The initial phase of acute management should include reviews every 1–2 weeks assessing 
the response, adherence to treatment, adverse effects and suicide risk. Mild or transient adverse 
effects (anxiety, nausea with SSRIs) can be managed by psychoeducation. More severe or persistent 
adverse effects may require a dose reduction, change to an antidepressant with a different adverse 
effect profile, non-pharmacological management (e.g. diet for weight gain with mirtazapine) or 
introduction of another medication (short-term benzodiazepines for anxiety, sildenafil or bupropion 
for sexual dysfunction).1  
Improvement of symptoms is often first noted during the first 1–2 weeks, and treatment 
options should be reviewed if there are no signs of improvement after 4 weeks. 
 
Next-step treatment for inadequate response 
Before deciding about next-step pharmacological treatment (Table 2), it is important to evaluate and 
address other factors that are possibly contributing to the lack of response.1 These include assessing 
adequacy of dose and treatment adherence, and reviewing the diagnosis, including possible 
psychiatric or medical co-morbidity, but also considering chronic social difficulties involved in 
maintaining the symptoms. If the review after 4 weeks of adequate treatment shows some 
improvement, it is recommended to continue treatment for another 2–4 weeks, but proceed with 
the next-step treatment if there is insufficient improvement at 6–8 weeks.  
Next-step drug treatment can consist of increasing the dose in the absence of significant 
adverse effects and if there has been some improvement, particularly with drugs with established 
dose–response relationships such as venlafaxine, escitalopram and TCAs, and bearing in mind the 
lack of good evidence for this strategy with other SSRIs.  
Another next-step treatment option is switching to another antidepressant. This can be 
initially within the same antidepressant class (SSRIs), but after more than one failure, switching to a 
different class is recommended. The strongest evidence of improvement is for switching from an 
SSRI to venlafaxine, but there are also reports of improved remission rates after switching from SSRIs 
to bupropion, mirtazapine or vortioxetine and agomelatine. In the absence of potentially toxic 
interactions (i.e. fluoxetine to TCAs or monoamine oxidase inhibitors (MAOIs) to serotonergic drugs) 
switching or cross-tapering directly without a washout period is recommended.1  
Further options for next-step treatment are using add-on therapies (antidepressant 
augmentation) or combining antidepressants. Augmentation treatments with the strongest evidence 
are quetiapine, aripiprazole, risperidone (all used in lower doses than for antipsychotic effects) or 
lithium. The second-line recommendation includes augmentation with olanzapine or tri-
iodothyronine, or combination with bupropion, mirtazapine or buspirone. Further recommended 
options include adding lamotrigine, modafinil or intermittent ketamine infusions.  
 
Relapse prevention and treatment  
The goal of treatment should be full remission of symptoms, given the higher rates of relapse 
associated with persisting residual symptoms. Because of the increased risk of relapse during the 6 
months after recovering from depression, the recommendation is to continue the effective 
treatment for 6–9 months after the symptoms have improved in all patients. For patients with a 
higher risk of relapse, it is recommended to continue treatment for 1–2 years or even longer given 
that recurrence rates are 2–3-fold lower on long-term maintenance therapy for as long as it is 
continued .1  
If depressive symptoms deteriorate while the patient is on continuation treatment, review the 
dose and adherence, as well as possible psychiatric and medical co-morbidity and adverse social 
factors. Where a patient has stopped antidepressant treatment, this should be restarted at the 
appropriate dose. Patients experiencing a recent relapse despite continued treatment may benefit 
from support and monitoring even without changing the medication as relapses are often self-
limiting. Patients with persisting relapse may require an increased dose of antidepressant or to 
proceed with next-step treatments in accordance with the guidance above.1 
 
Stopping treatment 
Abrupt stopping of treatment can result in discontinuation symptoms. Management of these usually 
mild symptoms should include explanation and reassurance but may require recommencement and 
slower tapering of the used antidepressant or a switch to fluoxetine.4 
 
Other treatment options  
A detailed discussion is beyond the scope of this article, but the main options are summarized in 
Table 3. 
 
  
Table 1 Examples of advantages and disadvantages of selected antidepressant drugs and their dose 
range for acute treatment of depression based on the British National Formulary,5 British Association 
or Psychopharmacology guidelines1 and Maudsley Prescribing Guidelines in Psychiatry4 
 
 
Drug Group Advantage  Disadvantage 
Recommended as first-line treatment 
Sertraline (50–200 
mg/day) 
SSRI Most favourable 
efficacy-to-tolerability 
profile 
Nausea, sexual 
dysfunction 
Escitalopram (10–20 
mg/day) 
As above + 
possible QTc 
prolongation 
Mirtazapine (15–45 
mg/day) 
Noradrenergic and 
specific serotonergic 
antidepressant 
Higher response rates 
than duloxetine, 
fluoxetine, 
fluvoxamine and 
paroxetine 
Adverse effect profile 
includes sedation and 
weight gain 
Further treatment options if suitable in relation to adverse effect profile, previous responses or 
patient’s preference 
Venlafaxine (75–375 
mg/day) 
 SNRI More effective than 
SSRIs 
Higher drop-out rates 
due to adverse effects 
Clomipramine (30–
250 mg/day) 
TCAs Same as or higher 
efficacy than SSRIs 
Less tolerated than 
SSRIs, higher toxicity 
in overdose  Imipramine (75–300 
mg/day) 
Amitriptyline (75–200 
mg/day) 
Phenelzine (45–90 
mg/day) 
MAOI  More effective for 
‘atypical depression’ 
(increased 
appetite/weight gain, 
increased sleep, 
severe fatigue) than 
TCAs 
Risk of serious 
interaction with 
medications and food 
Duloxetine (60 
mg/day) 
 SNRI More effective than 
SSRIs for co-morbid 
pain 
Possible lower overall 
efficacy for depressive 
symptoms 
Agomelatine (25–50 
mg/day) 
Melatonin (MT1, MT2) 
agonist and 5HT2C 
antagonist 
Efficacy comparable to 
SSRIs and venlafaxine 
Risk of hepatotoxicity 
Vortioxetine (10–20 
mg/day) 
Serotonin modulator 
and stimulator   
Similar efficacy to 
SSRI/SNRI medications 
Similar tolerability to 
SSRI/SNRI medications 
SNRI, Serotonin-noradrenaline reuptake inhibitor. 
  
Table 2 Next-step drug treatments based on the British Association or Psychopharmacology 
guidelines1 and Maudsley Prescribing Guidelines in Psychiatry4 
 Drug Advantage Disadvantage 
Switch to another antidepressant 
 Another SSRI See Table 1 
Venlafaxine  
Mirtazapine 
Vortioxetine 
Agomelatine 
Consider TCA or MAOI 
Augmentation or combination 
First line Quetiapine (150–300 
mg/day) 
Well tolerated, 
good evidence 
Sedation, weight 
gain  
Aripiprazole (2.5–10 
mg/day) 
Well tolerated, 
good evidence 
Akathisia, agitation 
Risperidone (0.5–2 
mg/day) 
Well tolerated Hyperprolactinemia, 
extrapyramidal 
symptoms  
Lithium (600–1200 
mg/day for plasma 
concentration 0.4–1.0 
mmol/litre) 
Good evidence Acute toxicity with 
narrow therapeutic 
window, requires 
plasma level 
monitoring; thyroid 
and renal effects 
Second line Olanzapine (2.5–10 
mg/day) 
Well tolerated Sedation, weight 
gain 
Tri-iodothyronine (20–
50 microgram/day) 
Well tolerated Requires thyroid 
function monitoring 
Bupropion (up to 400 
mg/day) 
Well tolerated Off licence in UK 
Mirtazapine (30–45 
mg/day) 
See Table 1 
Mianserin (30 mg/day) Well tolerated Risk of blood 
dyscrasias 
Buspirone (up to 60 
mg/day) 
Some evidence Less well tolerated 
Others Lamotrigine (200–400 
mg/day) 
Widely used Risk of rash, requires 
slow titration 
Modafinil (100–400 
mg/day) 
Rapid effect Can worsen anxiety 
Ketamine (0.5 mg/kg 
intravenously over 40 
minutes) 
Rapid effect Not widely available, 
possible negative 
cognitive effects, 
duration of effect 
unknown, bladder 
toxicity 
 
 
Table3 Non-pharmacological treatments of depression based on the British Association or 
Psychopharmacology guidelines1 and NICE guideline on depression in adults4 
Treatment Advantages Disadvantages 
Psychological therapy Efficacy of cognitive 
behavioural therapy, 
interpersonal therapy and 
behavioural activation is 
comparable to antidepressants 
for mild/moderate depression 
Requires active engagement of 
patients, availability can be 
variable with local services 
 ECT Good efficacy, including for 
severe and treatment-resistant 
depression, quicker onset than 
antidepressants 
High relapse rates, cognitive 
adverse effects (usually 
temporary) 
Repetitive transcranial 
magnetic stimulation  
Reasonable evidence, no major 
adverse effects 
Not widely used, less effective 
than ECT 
Vagus nerve stimulation  Efficacy comparable to 
pharmacotherapy and 
psychotherapy in open studies 
Invasive procedure, not widely 
used, lack of evidence from 
randomized controlled trials 
Bright light therapy Reasonable efficacy for 
seasonal affective disorder 
Limited evidence for non-
seasonal depression 
Supervised aerobic exercise Can be effective as adjunct to 
antidepressants 
Not recommended as an 
alternative to antidepressants 
ECT, electroconvulsive therapy. 
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